为了探讨艾迪注射液联合NP方案治疗非小细胞肺癌的疗效及其生存质量的影响对52例晚期NSCLC患者随机分组分为艾迪联合NP方案组26例艾迪50ml、静脉滴入1次/d连用7～10天长春瑞滨(NVB)30mg/m2d1.8,顺铂(DDP)25mg/m2静脉滴入1次/dd1～d3,21天为一个周期,NP方案组26例NVB和DDP用量同前艾迪联合NP方案组近期有效率53.8%(14/26)NP方案组42.3%(11/26)差异无统计学意义X2=0.04p>0.05临床受益率(CR+PR+SD)艾迪联合NP方案组(86.4%)高于(68.4%)P<0.05艾迪联合NP方案组化疗时生存质量优于NP方案组x2=11.12p<0.05初步研究结果提示艾迪注射液联合NP方案治疗晚期非小细胞肺癌能增加疗效改善患者生存质量并且有保护骨髓功能。

Objective:To Observe the efficacy and toxic and side effect of Gerfitinib(ZD1839) in treatinent of non-small cell lung cancer. Methods: From Feb.2005 to Feb.2006,oral Gefitinib in dose of 250mg daily were given in 32 patients with advanced non-small cell lung cancer.Results: 2 of 32 patients(6.25%)had complete response(CR),5(15.63%) Partial response(PR).7 of 32 patients(21.88%) was effective to the medicine.The condition in 15 patients wasstable including 14 ones with stable duration more than or equal to 24 Weeks.So the effective rate was 65.63%.10 Patients had progressive diseases.The adverse reaction induced by medication was skin rash in 15 patients,nausea in 8 ones,diarrhea in 7 ones,Xerosis cutis in 4 ones and fatigue in 2 ones.Other adverse reaction included fever,dental ulcer and athralgia(5%),There was no abnormal laboratory index.Conclusion: Gefitinib is effective in treatment of advanced non-small cell lung cancer,with less toxi C and side effect and better tolerance.The medication should be recommeded.

近年来,我们运用贞芪扶正胶囊配合化疗对102例恶性肿瘤病人进行治疗,在减轻毒性及改善生活质量方面取得较满意的结果,现报道如下.

联合化疗在中晚期非小细胞(NSCLC)肺癌的综合治疗中占有重要地位.近年来,国内外学者先后报道了多种用于NSCLC治疗的化疗方案,非小细胞肺癌化疗效果明显低于小细胞肺癌.随着铂类,植物碱,蒽琨类等药物的作用疗效有明显提高,1998～2000年我们采用西艾克(VDS)加环磷酰胺+阿霉素+卡帕(CAC)方案治疗中晚期非小细胞肺癌取得了较好疗效,现报告如下.

依据传统蒙医药方结合现代医学理论和技术,对32例肺癌患者采用随机数字表法,用西药、蒙西药物联合用药分组治疗,结果表明西药和蒙药联合应用治疗肺癌合并症、咳嗽、咳痰、痰中带血、胸痛,比单用西药疗效显著(P＜0.05),这对进一步有效地治疗肺癌病奠定了基础.